This process further slows the progression of liver fibrosis and cirrhosis through reducing cell death [3]
When used off-label, however, your insurance likely wont cover it
A recent open label trial compared the efficacy of drugs currently used to lower ICP in IIH (amiloride, furosemide, spironolactone and topiramate) and found a marginal reduction in ICP with no difference between drugs [11]
Practical Dosing and Administration Considerations BPC-157 is most commonly administered through subcutaneous injection, though oral capsules and nasal spray formulations are also marketed online
Combination Protocols: Often paired with Thymosin Alpha-1 (immune support), TB-500 (systemic repair), or detox protocols for mold illness to reduce Herxheimer-type reactions
No, GLP-1 receptor agonists are not diuretics and do not directly cause increased urination